Literature DB >> 19915582

In vivo assessment of mitochondrial toxicity of metacavir in Rhesus monkeys after three months of intravenous administration.

Wen Zeng1, An-chun Cheng, Zheng-li Chen, Qi-hui Luo, Yu-bo Sun, Zhan Li, Feng-jun Bi.   

Abstract

AIM: To explore the potential mitochondrial toxicities and their severities of intravenously administered metacavir, a nucleoside analog, in rhesus monkeys.
METHODS: Totally 21 rhesus monkeys were randomly divided into 4 groups: metacavir 120 mg/kg group, metacavir 40 mg/kg group, zidovudine(AZT) 50 mg/kg group, and blank control group. Animals were killed after the completion of dosing or further observed in a 4-week recovery phase. Changes of structure of mitochondria in liver, kidney, skeletal muscles, and cardiac muscles were observed under transmission electron microscope(TEM). Changes of the activities of mitochondrial respiratory chain complexes and mitochondrial DNA were also determined.
RESULTS: In metacavir 120 mg/kg group, some mitochondrial injuries were found in skeletal muscle, cardiac muscle, and liver, including that some cristae was broken and became sparse in density in the skeletal muscle, the morphology and size of mitochondria remained unchanged. Metacavir decreased the activities of respiratory chain complexes I and II and the mtDNA contents in three tissues in a dose-dependent manner; however, the extent of such decrease was lower than that in AZT 50 mg/kg group. The mitochondrial injuries in metacavir 40 mg/kg group were mild in each tissue and no obvious change in mitochondrial function was noted. On week 4 in the recovery phase, results showed that all these injuries were reversible after drug withdrawal.
CONCLUSION: These results suggest that metacavir has not a high risk for potential mitochondrial-related effects in rhesus monkeys.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19915582      PMCID: PMC4007497          DOI: 10.1038/aps.2009.163

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  29 in total

Review 1.  Mitochondrial dna depletion, oxidative stress, and mutation: mechanisms of dysfunction from nucleoside reverse transcriptase inhibitors.

Authors:  W Lewis; W C Copeland; B J Day
Journal:  Lab Invest       Date:  2001-06       Impact factor: 5.662

Review 2.  Mitochondrial toxicity and HIV therapy.

Authors:  A J White
Journal:  Sex Transm Infect       Date:  2001-06       Impact factor: 3.519

3.  Lactic acidosis and hepatic steatosis associated with use of stavudine: report of four cases.

Authors:  K D Miller; M Cameron; L V Wood; M C Dalakas; J A Kovacs
Journal:  Ann Intern Med       Date:  2000-08-01       Impact factor: 25.391

4.  An evaluation of the toxicities of 2'-fluorouridine and 2'-fluorocytidine-HCl in F344 rats and woodchucks (Marmota monax).

Authors:  F C Richardson; B C Tennant; D J Meyer; K A Richardson; P C Mann; G R McGinty; J L Wolf; P M Zack; R A Bendele
Journal:  Toxicol Pathol       Date:  1999 Nov-Dec       Impact factor: 1.902

Review 5.  Adverse effects of antiretroviral therapy.

Authors:  A Carr; D A Cooper
Journal:  Lancet       Date:  2000-10-21       Impact factor: 79.321

6.  Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicity.

Authors:  G Moyle
Journal:  Clin Ther       Date:  2000-08       Impact factor: 3.393

Review 7.  Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity.

Authors:  T N Kakuda
Journal:  Clin Ther       Date:  2000-06       Impact factor: 3.393

8.  Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors.

Authors:  Gabriel Birkus; Michael J M Hitchcock; Tomas Cihlar
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

9.  A sensitive and specific liquid chromatography-mass spectrometry method for determination of metacavir in rat plasma.

Authors:  Zhan Li; Xin Huang; Zhenzhou Jiang; Yajie Xiao; Chunhui Liu; Luyong Zhang; Bin Shu; Jingfeng Huang; Tao Li; Tao Wang; Feng Wang
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2008-01-04       Impact factor: 3.205

Review 10.  Antiretroviral therapy and the lipodystrophy syndrome.

Authors:  M John; D Nolan; S Mallal
Journal:  Antivir Ther       Date:  2001-03
View more
  4 in total

1.  Evaluation of mitochondrial toxicity in Marmota himalayana treated with metacavir, a novel 2',3'-dideoxyguanosine prodrug for treatment of hepatitis B Virus.

Authors:  Pinghu Zhang; Luyong Zhang; Zhenzhou Jiang; Yating Xiong; Hongkui Chen; Yuanqing Tao; Maozhi Hu; Zhan Li
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

2.  Reproductive toxicity study with a novel deoxyguanosine analogue (Metacavir) in pregnant SD rats.

Authors:  Qihui Luo; Zhengli Chen; Anchun Cheng; Mingshu Wang; Jing Fang; Xi Peng; Li Tang
Journal:  Front Med       Date:  2014-12-18       Impact factor: 4.592

3.  In vitro mitochondrial toxicity of metacavir, a new nucleoside reverse transcriptase inhibitor for treatment of hepatitis B virus.

Authors:  Pinghu Zhang; Luyong Zhang; Zhenzhou Jiang; Tao Wang; Hongkui Chen; Yating Xiong; Zhan Li
Journal:  Antimicrob Agents Chemother       Date:  2010-08-30       Impact factor: 5.191

4.  Diastolic dysfunction in spontaneous type 2 diabetes rhesus monkeys: a study using echocardiography and magnetic resonance imaging.

Authors:  Can Qian; Li Gong; Zunyuan Yang; Wei Chen; Yushu Chen; Ziqian Xu; Bing Wu; Chungui Tang; Fabao Gao; Wen Zeng
Journal:  BMC Cardiovasc Disord       Date:  2015-06-26       Impact factor: 2.298

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.